AFIB | Ticker Profile - Titan Protect

AFIB

Acutus Medical, Inc.

Healthcare · Medical Devices · PNK

$0.00

Data: 2026-05-14

✗ ETHICAL FAIL

MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2,991

Total market value of the company

Trailing P/E

0.00

Forward P/E

0.00

Based on estimated future earnings — lower means cheaper

Rev Growth

+203.7%

Year-over-year revenue change

Profit Margin

-47.4%

How much profit the company keeps from each dollar of revenue

ROE

0.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Acutus Medical, Inc.

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

https://www.acutusmedical.com

Country: United States Employees: 85 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

1,195,720.5% FAIL

Debt must be below 33% of total assets

Cash Ratio

468,706.1% FAIL

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.309

Excellent risk-adjusted returns

Kelly Fraction

0.1447

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

-0.941

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-94.0%

Historical annualised return based on price data

Max Drawdown

-100.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

6.14

Significantly more volatile than the market

52W High

$0.03

99% below the year high

52W Low

$0.00

100% above the year low

Avg Volume

2,392

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

1.9%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.15

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.00

Conservative use of debt — low financial risk

Current Ratio

2.06

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.61

Like current ratio but excludes inventory — stricter test

Gross Margin

5.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-21.8%

Profit from core operations before interest and tax

Free Cash Flow

$-6,777,125

Negative — the business is spending more than it generates

Revenue (TTM)

$20M

Total revenue over the last 12 months

Net Income

$-4,536,000

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Before you go